updated 2/2/2011 8:46:04 AM ET 2011-02-02T13:46:04

DELRAY BEACH, Fla., Feb. 2, 2011 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or the "Company") (Nasdaq:PSID) announced today that it has appointed former U.S. Ambassador Ned L. Siegel to its Board of Directors. Mr. Siegel, who also served the United Nations and Overseas Private Investment Corporation (OPIC), has significant relationships in Israel, where the Company is currently developing its Easy Check™ breath glucose detection device.

Mr. Siegel was nominated by President George W. Bush in May 2007 to serve as the Ambassador Extraordinary and Plenipotentiary of the United States of America to the Commonwealth of The Bahamas. During his fifteen-month tenure as Ambassador, he served as Chief of Mission responsible for all operations of Embassy Nassau. Prior to serving as Ambassador, Mr. Siegel was appointed by President George W. Bush to serve as a Representative of the United States to the United Nations, where he served in New York from September 2006 to January 2007, under Ambassador John R. Bolton as a Senior Advisor to the U.S. Mission to the 61st Session of the United Nations General Assembly.

In 2003, Mr. Siegel was honored by President George W. Bush with a Presidential Appointment to the Board of Directors of the OPIC, which was established as a development agency of the U.S. government in 1971 to help U.S. businesses invest overseas. Mr. Siegel served as a member of the OPIC Board of Directors until September of 2007.

Scott R. Silverman, Chairman and CEO of PositiveID, said, "We are honored to add Ambassador Siegel, who has an impressive record of service and successes within both the government and private sectors, to our board. We believe his strong and relevant relationships among government, financial and medical communities in Israel will be beneficial as we continue the development of and look to begin testing our Easy Check breath glucose detection device and other healthcare products."

About PositiveID Corporation

PositiveID Corporation develops and markets healthcare and information management products through its diagnostic devices and identification technologies, and its proprietary disease management tools. PositiveID's implantable healthcare devices and external hardware and software products are designed to communicate wirelessly to improve healthcare and the patient's quality of life. For more information on PositiveID, please visit www.PositiveIDCorp.com .

The PositiveID Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7717

Statements about PositiveID's future expectations, including the likelihood that Mr. Siegel's relationships among government, financial and medical communities in Israel will be beneficial as the Company continues the development of and looks to begin testing its Easy Check breath glucose detection device and other healthcare products, and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include the Company's ability to successfully develop and commercialize the Easy Check breath glucose detection device as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 19, 2010, and the Company's 10-Qs filed on May 6, 2010, August 13, 2010, and November 12, 2010, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

CONTACT: Allison Tomek
         561-805-8000
         atomek@positiveidcorp.com
         
         Dan Schustack
         CEOcast
         212-732-4300
         dschustack@ceocast.com

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 4.40%
$30K home equity loan FICO 5.80%
$75K home equity loan FICO 4.54%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.70%
13.70%
Cash Back Cards 17.66%
17.91%
Rewards Cards 17.05%
17.17%
Source: Bankrate.com